The National Institute for Health and Clinical Excellence (NICE) in 2019 have just published their updated topics in the diagnosis and management of new prostate cancer (1). This is a welcome update to a much-needed area by using evidence to guide the best way to diagnose and manage a growing disease demographic. Particularly welcome is the acknowledgment of active surveillance on an equal footing with radical therapies for men with low-risk and intermediate-risk disease. NICE therefore continues to recommend" all options" for these men but not that surveillance is the preferred option.
BJU international. 2019 Sep 12 [Epub ahead of print]
Vincent J Gnanapragasam
Academic Urology Group, Department of Surgery, University of Cambridge, UK.